Management ChangeAug 6, 2026, 05:33 PM
Apimeds Pharmaceuticals Appoints Dr. Christopher Kim as CSO
AI Summary
Apimeds Pharmaceuticals US, Inc. announced the appointment of Dr. Christopher Kim as its Chief Scientific Officer, effective August 5, 2026. In this role, Dr. Kim will be responsible for leading the scientific, clinical, and regulatory development of the company's APITOX program, encompassing research, clinical strategy, and regulatory approvals. His long-standing association with the APITOX program and extensive expertise are expected to provide continuity and strengthen the company's development strategy.
Key Highlights
- Apimeds Pharmaceuticals US, Inc. appointed Dr. Christopher Kim as Chief Scientific Officer.
- The appointment was effective immediately on August 5, 2026.
- Dr. Kim will lead the scientific, clinical, and regulatory development of the APITOX program.
- His responsibilities include research and development, clinical strategy, and regulatory engagement.
- Dr. Kim has extensive scientific, technical, and regulatory expertise related to the APITOX program.
Price Impact
More from APUS